Leaders in Pharmaceutical Business Intelligence (LPBI) Group

MabVax Therapeutics fully human monoclonal antibody HuMab 5B1

Reporter: Aviva Lev-Ari, PhD, RN

MabVax’s HuMab 5B1 antibody (“5B1”) we are referring to an antibody produced by an actual human in response to a vaccine constructed to elicit an antibody response to a specific cancer antigen.

Recently, a series of successful studies were conducted on 5B1 and presented at the 2015 World Molecular Imaging Conference (WMIC) in September. These experiments showed the remarkable utility of this antibody and what it can potentially become.

HuMab 5B1 Dual Therapeutic and Diagnostic Approach

Our dual approach to the development of HuMab 5B1 gives us the potential to penetrate a substantial pancreatic cancer imaging market independent of the development success of HuMab 5B1 as a therapeutic.

Application as an Antibody Drug Conjugate: We are collaborating with Heidelberg Pharma to test an ADC using our HuMab 5B1 antibody and Heidelberg’s linker and toxin technology in animal models of pancreatic cancer. The results of both the in vitro and in vivo experiments provide strong support for moving the program into further preclinical and eventually clinical development.

Sourced through Scoop.it from: www.mabvax.com

See on Scoop.it – Cardiovascular Disease: PHARMACO-THERAPY